Mera kal pharmacological and toxicological screening ka papar he or usme anti diabetic aa rha he toh mujhe iske ek simple exam form answer bna ke do or sb cheez ka acche se define Krna procedure charform me ekdam simple language me btna so that ki ekbar me samaj me ajye ye dhyan rkhna ki teacher kisi bhi tarah no na kaat paye or ha samjne ke liye hinglish ka istemal kr skte ho par mujhe answer exam form me chaiye so that english me likh sake but simple language

Reading File

Finding Sources

Searching PubMed

"Diabetes Mellitus, Type 2"[MeSH Terms] AND antidiabetic agents

Searching the Web

ADA Standards of Care 2026 pharmacologic approaches glycemic treatment type 2 diabetes

Finding Sources

Searching the Web

OECD Test Guideline 423 acute oral toxicity procedure official

Pharmacological and Toxicological Screening of Antidiabetic Drugs

Definition

Antidiabetic drugs are medicines that lower increased blood glucose level and help in the treatment of diabetes mellitus.

Pharmacological screening means testing a new drug or plant extract in suitable experimental animals to find whether it has antidiabetic activity.

Toxicological screening means testing the safety of the drug or extract and finding the harmful dose before pharmacological testing.

1. Introduction

Diabetes mellitus is a metabolic disease in which blood glucose level becomes high due to:

Deficiency of insulin secretion
Decreased action of insulin
Or both

Antidiabetic drugs are mainly used in Type 2 diabetes mellitus. Examples include metformin, sulfonylureas, pioglitazone, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and insulin.

Metformin lowers hepatic glucose production and improves peripheral glucose use.
Simple meaning: It reduces glucose made by the liver and helps the body use glucose better.

Current treatment selection is based on blood glucose control, risk of hypoglycaemia, body weight, kidney function, heart disease, and patient factors, as described in the ADA pharmacological guidance.

2. Objectives

To evaluate the antidiabetic activity of a test drug or herbal extract.
To compare the activity of test drug with a standard antidiabetic drug.
To measure reduction in blood glucose level.
To determine whether the drug is safe before giving it to animals.
To identify signs of toxicity and estimate the safe dose range.

3. Principle

A diabetic condition is produced in experimental animals, usually rats or mice. The test drug is administered, and blood glucose is measured at different time intervals.

If the test drug produces a significant decrease in blood glucose level compared with diabetic control animals, it is considered to have antidiabetic activity.

4. Experimental Animals

Albino rats or mice are commonly used.
Healthy animals of either sex may be selected as per the approved institutional protocol.
Animals should be maintained under standard laboratory conditions.
They should receive standard pellet diet and water.
Before glucose testing, animals are generally fasted overnight, with water allowed.

Note: All animal experiments must be performed only after approval from the Institutional Animal Ethics Committee (IAEC) and according to CPCSEA or institutional rules.

5. Methods Used for Antidiabetic Screening

The commonly used methods are:

Oral Glucose Tolerance Test (OGTT)
Alloxan-induced diabetic model
Streptozotocin-induced diabetic model
Diet-induced insulin-resistance model

For an exam answer, write OGTT and alloxan-induced diabetes in detail.

A. Oral Glucose Tolerance Test (OGTT)

Aim

To study the ability of a test drug to reduce the rise in blood glucose after administration of glucose.

Principle

After giving glucose orally, blood glucose level rises. A good antidiabetic drug reduces this rise faster than the control group.

Requirements

Experimental rats or mice
Glucose solution
Test drug or test extract
Standard drug: Metformin or glibenclamide
Glucometer or blood glucose estimation kit
Oral feeding needle
Blood sample collection materials

Grouping of Animals

Animals are divided into groups, commonly 5 to 6 animals per group.

Group	Treatment
Group I	Normal control - vehicle only
Group II	Glucose control - glucose only
Group III	Standard group - standard antidiabetic drug + glucose
Group IV	Test group I - low dose of test drug + glucose
Group V	Test group II - high dose of test drug + glucose

Procedure

Fast the animals overnight. Water is allowed.
Measure the initial blood glucose level. This is called 0 minute value.
Give the test drug or standard drug orally to the respective groups.
After a fixed time, usually 30 minutes, administer glucose orally to all groups except normal control if the protocol requires.
Collect blood samples at 30, 60, 90, and 120 minutes.
Measure blood glucose using a glucometer or biochemical method.
Compare glucose levels of test groups with glucose control group.

Flow Chart

Select healthy animals
        ↓
Fast overnight
        ↓
Measure fasting blood glucose
        ↓
Divide animals into groups
        ↓
Give vehicle / standard drug / test drug
        ↓
After 30 minutes give oral glucose
        ↓
Measure blood glucose at 0, 30, 60, 90 and 120 min
        ↓
Compare results statistically
        ↓
Decrease in blood glucose = Antidiabetic activity

Observation

A graph is drawn between:

X-axis: Time in minutes
Y-axis: Blood glucose level in mg/dL

The glucose control group shows a high rise in blood glucose.
The standard and test groups show lower glucose levels if they possess antidiabetic activity.

Result

If the test drug significantly reduces blood glucose level or glucose area under curve compared with glucose control, it shows antidiabetic activity.

B. Alloxan-Induced Diabetic Model

Aim

To evaluate antidiabetic activity of a test drug in alloxan-induced diabetic rats.

Principle

Alloxan selectively damages pancreatic beta cells. Beta cells are responsible for insulin secretion. Due to beta-cell damage, insulin decreases and blood glucose increases. This produces an experimental diabetic condition.

Simple Hinglish: Alloxan pancreas ke beta cells ko damage karta hai. Insulin kam ho jata hai, isliye blood glucose badh jata hai.

Requirements

Albino rats
Alloxan monohydrate
Test drug or test extract
Standard drug: Metformin or glibenclamide
Glucometer
Normal saline or suitable vehicle
Oral feeding needle

Groups

Group	Treatment
Group I	Normal control
Group II	Diabetic control
Group III	Diabetic + standard drug
Group IV	Diabetic + test drug low dose
Group V	Diabetic + test drug high dose

Procedure

Select healthy rats and fast them overnight.
Record fasting blood glucose level.
Induce diabetes by administering alloxan according to the approved animal protocol.
Since alloxan can initially cause a sudden fall in glucose, animals are given glucose solution after induction to avoid severe hypoglycaemia.
After 48 to 72 hours, measure blood glucose.
Animals showing high blood glucose are considered diabetic and selected for the study.
Divide diabetic animals into different groups.
Give vehicle, standard drug, and test drug daily for the selected study period, commonly 7, 14, or 21 days.
Measure blood glucose at fixed intervals.
At the end of study, body weight and biochemical parameters may also be measured.

Flow Chart

Healthy rats selected
        ↓
Overnight fasting
        ↓
Record fasting blood glucose
        ↓
Administer alloxan to induce diabetes
        ↓
Give glucose solution to prevent severe hypoglycaemia
        ↓
Wait for 48-72 hours
        ↓
Measure blood glucose
        ↓
Select diabetic rats
        ↓
Make groups: diabetic control, standard and test groups
        ↓
Administer treatment daily
        ↓
Measure blood glucose and body weight
        ↓
Compare results with diabetic control

Parameters Evaluated

Fasting blood glucose level
Percentage reduction in blood glucose
Body weight
Serum insulin, if facility is available
HbA1c in long-duration studies
Lipid profile
Liver and kidney function tests
Histopathology of pancreas, if required

Formula

[ \text{Percentage reduction in blood glucose} = \frac{\text{Blood glucose of diabetic control - Blood glucose of treated group}} {\text{Blood glucose of diabetic control}} \times 100 ]

Result

If the test group shows a significant reduction in blood glucose compared with the diabetic control group, the test substance possesses antidiabetic activity.

6. Standard Drugs Used

Standard Drug	Class	Main Action
Metformin	Biguanide	Reduces glucose production by liver and improves insulin sensitivity
Glibenclamide	Sulfonylurea	Stimulates insulin release from pancreatic beta cells
Pioglitazone	Thiazolidinedione	Improves insulin sensitivity in tissues
Insulin	Hormone	Directly lowers blood glucose by increasing glucose uptake

Important point: Glibenclamide needs functioning pancreatic beta cells for proper action. Metformin mainly reduces glucose production by the liver.

7. Toxicological Screening of Antidiabetic Test Drug

Definition

Toxicological screening is the study used to detect harmful effects of a test substance and to determine its safety before pharmacological testing.

Aim

To determine acute oral toxicity and select safe doses of the test drug or herbal extract for antidiabetic screening.

Common Method

Acute Oral Toxicity Study - OECD Guideline 423

OECD 423 is called the Acute Toxic Class Method. It uses fixed dose levels such as 5, 50, 300, and 2000 mg/kg body weight. The OECD guideline defines acute oral toxicity as adverse effects after a single oral dose or doses given within 24 hours. See the official OECD Test Guideline 423.

Procedure

Select healthy experimental animals.
Fast animals before administration of the test substance as per protocol.
Administer the test substance orally at a selected starting dose.
Observe animals carefully during the first few hours.
Continue observation for 14 days.
Record mortality and signs of toxicity.
Depending on mortality and toxic signs, use a lower or higher dose in the next group, following OECD 423 decision scheme.
Select one or two safe doses for pharmacological screening.

Toxicity Signs to Observe

Changes in skin and fur
Changes in eyes and mucous membranes
Salivation
Tremors
Convulsions
Drowsiness or sedation
Increased or decreased movement
Diarrhoea
Breathing difficulty
Coma
Death
Change in food intake
Change in body weight

Flow Chart of Acute Toxicity Study

Select healthy animals
        ↓
Fast animals as per approved protocol
        ↓
Give test substance orally at selected dose
        ↓
Observe continuously for first few hours
        ↓
Observe daily for 14 days
        ↓
Record toxic signs, body weight and mortality
        ↓
Follow OECD 423 dose progression
        ↓
Determine safe dose
        ↓
Use a fraction of safe dose for antidiabetic screening

Dose Selection for Pharmacological Study

If no mortality or serious toxicity is seen at a limit dose, lower fractions of the safe dose may be selected for pharmacological studies, for example:

Low dose
Medium dose
High dose

The exact dose should always be selected according to the approved institutional protocol and the study substance.

8. Precautions

Use healthy animals only.
Maintain the same environmental conditions for all groups.
Fast animals properly before glucose estimation.
Use correct dose and correct route of administration.
Handle alloxan carefully because it can cause severe hypoglycaemia initially.
Give glucose support after alloxan induction as required by protocol.
Measure blood glucose at the same time in all groups.
Use proper control, standard, and test groups.
Record all observations carefully.
Follow IAEC, CPCSEA, and OECD ethical guidelines.

9. Conclusion

Pharmacological screening helps to identify whether a new drug or plant extract has antidiabetic activity. OGTT is useful for checking glucose tolerance, while alloxan-induced diabetic rats are useful for evaluating blood glucose-lowering activity in experimental diabetes. Toxicological screening is performed first to determine safe doses and toxic effects. A substance that safely lowers blood glucose compared with diabetic control may be considered to possess antidiabetic potential.

One-Line Viva Answers

What is diabetes mellitus?
A metabolic disorder characterized by persistent high blood glucose due to deficient insulin secretion, reduced insulin action, or both.
What is pharmacological screening?
Testing a substance in experimental animals to identify its pharmacological activity.
What is toxicological screening?
Testing a substance to identify harmful effects and safe dose range.
Why is alloxan used?
It damages pancreatic beta cells and produces experimental diabetes.
Why is metformin used as standard?
It is a commonly used antidiabetic drug that reduces hepatic glucose production.
Why is glibenclamide used as standard?
It stimulates insulin release from pancreatic beta cells.
What is the full form of OECD?
Organisation for Economic Co-operation and Development.
What is the full form of OGTT?
Oral Glucose Tolerance Test.
What is the main parameter measured?
Blood glucose level in mg/dL.
What indicates antidiabetic activity?
Significant reduction in blood glucose level compared with diabetic or glucose control group.

This is a shared conversation. Sign in to Orris to start your own chat.